RAPP
Rapport Therapeutics, Inc. · Healthcare · Market cap $2.2B
Insiders sold $7.8M net in the last 90 days ·4 sellers, 0 buyers· 11 of 11 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 26, 2026
Insider Buying
$1.6M
reported purchases (SEC code P)
Insider Selling
$49.1M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Latest filing
Aug 26, 2026
Yeleswaram Krishnaswamy
Rapport Therapeutics, Inc. (RAPP) has 37 SEC Form 4 filings (84 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Aug 26, 2026.
Inside the rolling window, 8 insiders at Rapport Therapeutics, Inc. reported 3 open-market purchases totaling $1.6M and 39 open-market sales totaling $49.1M. The most active filer is Chief Executive Officer Ceesay Abraham with 12 filings. Insiders have net sold $43.6M over the trailing 6 months. The most recent open-market filing is a sale of 13,160 shares by Chief Development Officer Yeleswaram Krishnaswamy, dated Aug 24, 2026, worth $658K.
- Industry:Biotechnology
- CEO:Abraham N. Ceesay
- Employees:84
- HQ:Boston, MA, US
- IPO:2024-06-07
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Development Officer | Sale | 13,160 | $658K | Aug 26 | -12.8% | SEC ↗ | |
| Chief Development Officer | Sale | 37,000 | $1.9M | Aug 26 | -12.8% | SEC ↗ | |
| Chief Executive Officer | Sale | 18,921 | $938K | Aug 26 | -12.8% | SEC ↗ | |
Yeleswaram KrishnaswamyFirst in 4 months | Chief Development Officer | Sale | 404 | $20K | Aug 20 | -4.3% | SEC ↗ |
| Chief Executive Officer | Sale | 22,541 | $1.0M | Aug 12 | -4.1% | SEC ↗ | |
| Chief Executive Officer | Sale | 28,958 | $1.4M | Aug 12 | -4.1% | SEC ↗ | |
| Chief Executive Officer | Sale | 2,210 | $93K | Jul 29 | — | SEC ↗ | |
| Chief Executive Officer | Sale | 8,210 | $328K | Jul 15 | — | SEC ↗ | |
Gault CherylFirst in 3 months | Chief Operating Officer | Sale | 10,000 | $416K | Jul 1 | — | SEC ↗ |
Ceesay AbrahamFirst in 4 months | Chief Executive Officer | Sale | 8,220 | $327K | Jul 1 | — | SEC ↗ |
| 10% Owner | Sale | 18,572 | $744K | May 28 | — | SEC ↗ | |
| 10% Owner | Sale | 133,618 | $5.4M | May 13 | — | SEC ↗ | |
| 10% Owner | Sale | 271,495 | $10.9M | May 11 | — | SEC ↗ | |
| 10% Owner | Sale | 5,018 | $202K | May 11 | — | SEC ↗ | |
| Chief Development Officer | Sale | 20,225 | $809K | Apr 21 | — | SEC ↗ | |
Third Rock Ventures V, L.P.First filing | 10% Owner | Sale | 426,005 | $17.2M | Apr 21 | — | SEC ↗ |
| Chief Development Officer | Sale | 500 | $17K | Apr 14 | — | SEC ↗ | |
| Chief Development Officer | Sale | 9,165 | $321K | Apr 14 | — | SEC ↗ | |
| Chief Development Officer | Sale | 10,200 | $358K | Apr 14 | — | SEC ↗ | |
| Chief Development Officer | Sale | 360 | $13K | Apr 9 | — | SEC ↗ | |
| Chief Operating Officer | Sale | 10,000 | $282K | Mar 31 | — | SEC ↗ | |
| Chief Development Officer | Sale | 10,115 | $303K | Mar 26 | — | SEC ↗ | |
Gault CherylFirst in 3 months | Chief Operating Officer | Sale | 2,014 | $58K | Mar 9 | — | SEC ↗ |
| Chief Executive Officer | Sale | 10,916 | $320K | Feb 19 | — | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,500 | $247K | Feb 19 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does RAPP have?
Rapport Therapeutics, Inc. (RAPP) has 37 SEC Form 4 filings (84 transaction rows) in the rolling 365-day window, disclosed by 8 distinct insiders. Most recent filing: Aug 26, 2026.
When was the most recent SEC Form 4 filing for RAPP?
The most recent Form 4 filing for RAPP on Tracefour is dated Aug 26, 2026.
Who is the most active insider at RAPP?
The most active SEC Form 4 filer at RAPP in the rolling window is Chief Executive Officer Ceesay Abraham, with 12 filings.
What is the net insider flow at RAPP over the last 6 months?
Over the trailing 180 days, insiders at RAPP have net sold $43.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at RAPP in the current window?
Inside the rolling window, insiders at RAPP bought $1.6M and sold $49.1M based on SEC Form 4 filings.
Can I get alerts for RAPP insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Rapport Therapeutics, Inc. (RAPP). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Rapport Therapeutics, Inc. is in the Healthcare sector.